---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-001591"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:32:16.672135+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics prices $9M public offering of common stock and warrants

## Summary
- 1.6M shares or pre-funded warrants plus 3.2M common warrants at $5.65/unit.
- Gross proceeds ~$9M; net proceeds ~$8M after fees and expenses.
- Net proceeds to fund Phase 3 LEVEL trial of oral levosimendan in PH-HFpEF.
- Roth Capital Partners acted as exclusive placement agent; offering closed Feb 12, 2024.
- Post-offering shares outstanding: 1,766,023.

## SEC filing metadata
- accession: 0001654954-24-001591
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424001591/0001654954-24-001591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424001591/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-001591
- JSON: https://secwatch.observer/filing/0001654954-24-001591.json
- Plain text: https://secwatch.observer/filing/0001654954-24-001591.txt

## Key facts
- Material Agreements
  TENAX THERAPEUTICS, INC. entered into Warrant Agency Agreement with Direct Transfer LLC (effective 2024-02-12).
  - Action: entry
  - Counterparty: Direct Transfer LLC
  - Effective: 2024-02-12
  source text: On February 12, 2024, the Company also entered into a warrant agency agreement (the “Warrant Agency Agreement”) with the Company’s transfer agent, Direct Transfer LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Common Warrants.
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424001591/0001654954-24-001591-index.htm
- Material Agreements
  TENAX THERAPEUTICS, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $9.0 million (effective 2024-02-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Roth Capital Partners, LLC
  - Value: gross proceeds of approximately $9.0 million
  - Effective: 2024-02-08
  source text: On February 8, 2024, Tenax Therapeutics, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424001591/0001654954-24-001591-index.htm
- Material Agreements
  TENAX THERAPEUTICS, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $9.0 million (effective 2024-02-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain purchasers
  - Value: gross proceeds of approximately $9.0 million
  - Effective: 2024-02-08
  source text: On February 8, 2024, Tenax Therapeutics, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424001591/0001654954-24-001591-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.